<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21965" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fresh Frozen Plasma (FFP)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khawar</surname>
            <given-names>Hina</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kelley</surname>
            <given-names>Walt</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stevens</surname>
            <given-names>Joshua B.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Guzman</surname>
            <given-names>Nilmarie</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hina Khawar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Walt Kelley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Stevens declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nilmarie Guzman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21965.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fresh frozen plasma is indicated for the deficiency of coagulation factors with abnormal coagulation tests in active bleeding. Fresh frozen plasma is also indicated for a planned surgery or invasive procedure in the presence of abnormal coagulation tests, the reversal of warfarin in the presence of active bleeding, or a planned procedure when vitamin K is inadequate to reverse the warfarin effect, thrombotic thrombocytopenic purpura, and congenital or acquired factor deficiency with no alternative therapy. This activity reviews the indications for fresh frozen plasma and highlights the role of the interprofessional team in managing patients with coagulopathy who require fresh frozen plasma.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of fresh frozen plasma.</p></list-item><list-item><p>Determine&#x000a0;the adverse effects of fresh frozen plasma.</p></list-item><list-item><p>Apply&#x000a0;the appropriate monitoring of patients who are administered fresh frozen plasma.</p></list-item><list-item><p>Communicate&#x000a0;some interprofessional team strategies to improve care coordination and advance managing conditions treated with fresh frozen plasma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21965&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21965">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21965.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fresh frozen plasma is indicated for the deficiency of coagulation factors with abnormal coagulation tests in active bleeding. Fresh frozen plasma is also indicated for a planned surgery or invasive procedure in the presence of abnormal coagulation tests, for the reversal of warfarin in the presence of active bleeding, or planned procedure when vitamin K is inadequate to reverse the warfarin effect, thrombotic thrombocytopenic purpura, and congenital or acquired factor deficiency with no alternative therapy. Based on a systematic review, other specific recommendations for&#x000a0;fresh frozen plasma include trauma patients requiring massive transfusion and warfarin-related intracranial hemorrhage.&#x000a0;</p>
        <p>Other situations where the administration of fresh frozen plasma cannot be recommended for or against based on systematic review include fresh frozen plasma transfusion at a plasma-to-RBC ratio of 1&#x000a0;to 3 or more in trauma patients with massive transfusion. Conditions that cause the deficiency of multiple coagulation factors and may require the administration of fresh frozen plasma include liver disease and disseminated intravascular coagulation. Fresh&#x000a0;frozen plasma transfusion may not be tolerated in patients with liver disease as patients may not tolerate the infusion volumes necessary to achieve adequate hemostatic levels of coagulation factors.<xref ref-type="bibr" rid="article-21965.r1">[1]</xref><xref ref-type="bibr" rid="article-21965.r2">[2]</xref><xref ref-type="bibr" rid="article-21965.r3">[3]</xref></p>
      </sec>
      <sec id="article-21965.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fresh frozen plasma is the fluid portion of a unit of whole blood frozen in a designated time frame, usually within 8 hours. Fresh&#x000a0;frozen plasma contains all coagulation factors except platelets. Fresh&#x000a0;frozen plasma contains fibrinogen (400 to 900 mg/unit), albumin, protein C, protein S, antithrombin, and tissue factor pathway inhibitors. It is free of erythrocytes and leukocytes.&#x000a0; Fresh&#x000a0;frozen plasma corrects coagulopathy by replacing or supplying plasma proteins in patients deficient in or defective plasma proteins. A standard dose of 10 to 20 mL/kg (4 to 6 units in adults) raises factor levels by approximately 20%. Increasing roughly 10% of several factors is enough to bring about&#x000a0;hemostasis.&#x000a0;Also, fresh frozen plasma provides some volume resuscitation, as each unit contains approximately 250 mL.<xref ref-type="bibr" rid="article-21965.r4">[4]</xref><xref ref-type="bibr" rid="article-21965.r5">[5]</xref><xref ref-type="bibr" rid="article-21965.r6">[6]</xref><xref ref-type="bibr" rid="article-21965.r7">[7]</xref></p>
      </sec>
      <sec id="article-21965.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Fresh frozen plasma can only be administered intravenously. Fresh&#x000a0;frozen plasma must be ABO compatible with the recipient&#x02019;s red cells. Upon visual inspection, the&#x000a0;fresh frozen plasma container and fluid should have no leakage, clots, or abnormal color. Fresh&#x000a0;frozen plasma is stored at -30 Celsius. Before administration, fresh frozen plasma is thawed in a water bath at 30 to 37 Celsius over 20 to 30 minutes or in an FDA-cleared device as quickly as 2 to 3 minutes. Fresh&#x000a0;frozen plasma should be administered immediately after thawing. If fresh frozen plasma is not given immediately after thawing, it should be stored at 1 to 6 Celsius.&#x000a0;</p>
        <p>In some institutions, if the thawed fresh frozen plasma is not used in 24 hours, it is discarded. Some authorities advocated using thawed fresh frozen plasma for up to seven days. <xref ref-type="bibr" rid="article-21965.r8">[8]</xref>Once thawed, the activity of clotting factors, particularly factor V and factor VIII, declines gradually. After the initial dosage, re-administration may be needed every 6 to 8 hours if there is ongoing bleeding due to the short half-life of factor VII; factor VII has a half-life of 2 to 6 hours.</p>
      </sec>
      <sec id="article-21965.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of fresh frozen plasma administration are similar to those that pertain to whole blood and all blood components. They can be categorized into non-immunologic, immediate, and delayed immunologic complications.&#x000a0;The&#x000a0;acellularity of fresh frozen plasma spares certain disease transmission and blood immunogenicity: CMV and graft-versus-host disease cannot be transmitted by fresh frozen plasma as there are no viable leukocytes. Non-immunologic complications include the transmission of infectious agents, transfusion-associated circulatory overload (TACO), and metabolic complications like citrate toxicity. Infectious agents that are transmittable via fresh frozen plasma include HIV and hepatitis B and C. Screening and pathogen inactivation have reduced transmission rates of HIV to 1 in 7.8 million, hepatitis B virus to 1 in 153,000, and hepatitis C virus to 1 in 2.3 million.</p>
        <p>TACO&#x000a0;results from cardiogenic pulmonary edema and can occur after transfusion of excessive volumes or volumes at excessive rates. Immediate immunologic complications include hemolytic transfusion reaction, febrile non-hemolytic reaction, allergic reactions, anaphylactoid/anaphylactic reactions, and transfusion-related acute lung injury (TRALI). Hemolytic transfusion reaction occurs from anti-A and anti-B antibodies due to the failure of ABO matching.&#x000a0;TRALI is the most common cause of transfusion-related death. TRALI is the acute onset of hypoxemia and non-cardiogenic pulmonary edema in the absence of other causes of acute lung injury or circulatory overload. TRALI occurs secondary to stimuli in blood components (white blood cell antibodies from donors and/or pro-inflammatory molecules accumulated in stored blood components) that trigger an inflammatory response, injuring the alveolar-capillary membrane and causing permeability pulmonary edema. Delayed immunologic complications include alloimmunization to plasma proteins.<xref ref-type="bibr" rid="article-21965.r9">[9]</xref></p>
      </sec>
      <sec id="article-21965.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Fresh frozen plasma is contraindicated when coagulopathy can be corrected more effectively with specific therapy and when blood volume can be adequately replaced with other volume expanders. More specific treatments that merit consideration before fresh frozen plasma administration include vitamin K, cryoprecipitate antihemophilic factor, prothrombin complex concentrates, or specific coagulation factor concentrates like factor VII. Fresh frozen plasma should not be a volume expander without coagulation deficiencies and active bleeding. Fresh&#x000a0;frozen plasma is contraindicated for reversing anticoagulation induced by heparin, direct thrombin inhibitors, or direct factor Xa inhibitors because these medications do not effectively reverse anticoagulation. Antidotes to reverse direct oral anticoagulants are better options.</p>
      </sec>
      <sec id="article-21965.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The fresh frozen plasma therapy is monitored clinically with signs of bleeding and chemically with coagulation studies and fibrinogen levels. Each unit of fresh frozen plasma contains approximately 200 to 250 mL. Apheresis-derived units can contain as much as 400 to 600 mL. The 1 250 mL unit administration should raise the fibrinogen level by 5 to 10 mg/dl. The goal of therapy is a cessation of bleeding. The laboratory value goal is to correct the prothrombin time/activated partial thromboplastin time to less than 1.5 times normal.<xref ref-type="bibr" rid="article-21965.r10">[10]</xref><xref ref-type="bibr" rid="article-21965.r11">[11]</xref><xref ref-type="bibr" rid="article-21965.r12">[12]</xref></p>
      </sec>
      <sec id="article-21965.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Citrate toxicity can occur with the administration of fresh frozen plasma. Most citrate in whole blood products is present in fresh frozen plasma and platelets, not packed red blood cells. Citrate chelates calcium and citrate intoxication causes hypocalcemia. Hypocalcemia signs and symptoms include hypotension, decreased pulse pressure, arrhythmias, mental status changes, and tetany. Treatment includes calcium administration.</p>
      </sec>
      <sec id="article-21965.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There is a general assumption among healthcare workers that fresh frozen plasma is free of adverse effects and complications; nothing can be further from the truth. All interprofessional healthcare team members, including clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists, should know the indications for fresh frozen plasma administration and the monitoring process.&#x000a0;The adverse effects of fresh frozen plasma are monitored like any other blood product administration. The patient&#x02019;s vital signs (temperature, pulse, respiration, and blood pressure) are monitored before, during, and after administration. If a reaction is noted based on signs and symptomology, treatment is guided by the type of transfusion reaction. Usually, the administration&#x000a0;of the product should immediately cease. Life-threatening reactions like TRALI and TACO may require aggressive respiratory support and often mechanical ventilation.</p>
        <p>Proper administration and management of&#x000a0;fresh frozen plasma require the efforts of an entire interprofessional team. Through proper knowledge and training, open information sharing and communication, and empowerment of each team member to contribute from their specialties, patients can achieve the best possible outcomes where&#x000a0;fresh frozen plasma is indicated while having minimal adverse events.</p>
      </sec>
      <sec id="article-21965.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21965&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21965">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21965/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21965">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21965.s11">
        <title>References</title>
        <ref id="article-21965.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sartori</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Sivolella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Pasquale</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Saggiorato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boscaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic protocol for dental care in ligneous gingivitis due to severe plasminogen deficiency: Case report and review of literature.</article-title>
            <source>Haemophilia</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>693</fpage>
            <page-range>693-698</page-range>
            <pub-id pub-id-type="pmid">30994256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alwan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vendramin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liesner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dutt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gooding</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biss</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rayment</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cranfield</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Veen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>QA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Motwani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Priddee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Alamelu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyall</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Westwood</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Characterization and treatment of congenital thrombotic thrombocytopenic purpura.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Apr</month>
            <day>11</day>
            <volume>133</volume>
            <issue>15</issue>
            <fpage>1644</fpage>
            <page-range>1644-1651</page-range>
            <pub-id pub-id-type="pmid">30770395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shamshirian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohseni</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Pourfathollah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Mehdipour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghorbanpour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A review of blood usage and wastage in a tertiary heart center.</article-title>
            <source>Acta Clin Belg</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-103</page-range>
            <pub-id pub-id-type="pmid">30513064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Diong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Gopalakrishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Linn</surname>
                <given-names>YC</given-names>
              </name>
            </person-group>
            <article-title>Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant.</article-title>
            <source>Transfusion</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>335</fpage>
            <page-range>335-339</page-range>
            <pub-id pub-id-type="pmid">30467850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>de Lloyd</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collis</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience.</article-title>
            <source>Int J Obstet Anesth</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>37</volume>
            <fpage>106</fpage>
            <page-range>106-117</page-range>
            <pub-id pub-id-type="pmid">30322667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: A case report and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>38</issue>
            <fpage>e12044</fpage>
            <pub-id pub-id-type="pmid">30235659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsunaga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Fibrinogen for the management of critical obstetric hemorrhage.</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">30155944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selleng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>10 Years of Experience with the First Thawed Plasma Bank in Germany.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>350</fpage>
            <page-range>350-357</page-range>
            <pub-id pub-id-type="pmid">35082566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cho</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Transfusion-Related Acute Lung Injury</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29939623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haaga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rahim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kondray</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakamoto</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Local Injection of Fresh Frozen Plasma to Traditional Methods of Hemostasis in Minimally Invasive Procedures.</article-title>
            <source>Acad Radiol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>1617</fpage>
            <page-range>1617-1623</page-range>
            <pub-id pub-id-type="pmid">29573937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carothers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giancarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Activated prothrombin complex concentrate for warfarin reversal in traumatic intracranial hemorrhage.</article-title>
            <source>J Surg Res</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>223</volume>
            <fpage>183</fpage>
            <page-range>183-187</page-range>
            <pub-id pub-id-type="pmid">29433872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21965.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chowdary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Besser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Creagh</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rokicka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nokes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Diprose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>1159</fpage>
            <page-range>1159-1169</page-range>
            <pub-id pub-id-type="pmid">29415562</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
